A Pharmacokinetics, Pharmacodynamics and Safety Study of Rabeprazole in New Born Infants With Gastroesophageal Reflux Disease (GERD)
- First Posted Date
- 2009-03-04
- Last Posted Date
- 2013-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 69
- Registration Number
- NCT00855361
A Study of Single and Multiple Doses of Rabeprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Months Old, Inclusive
Phase 1
Completed
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- Interventions
- First Posted Date
- 2008-09-05
- Last Posted Date
- 2013-07-08
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 51
- Registration Number
- NCT00747526
A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2008-05-19
- Last Posted Date
- 2013-09-19
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 2051
- Registration Number
- NCT00679627
Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma
Phase 2
Completed
- Conditions
- Multiple Myeloma
- Interventions
- Other: MethylprednisoloneOther: Dexamethasone
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2018-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 104
- Registration Number
- NCT00574288
An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 57
- Registration Number
- NCT00544440
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
Phase 2
Terminated
- Conditions
- Colitis, Ulcerative
- Interventions
- First Posted Date
- 2007-06-20
- Last Posted Date
- 2013-06-14
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 291
- Registration Number
- NCT00488774
Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.
Phase 3
Completed
- Conditions
- SchizophreniaPsychotic DisordersSchizophrenic DisordersDementia Praecox
- Interventions
- First Posted Date
- 2007-06-20
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 400
- Registration Number
- NCT00488319
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
Phase 3
Completed
- Conditions
- Colitis, Ulcerative
- Interventions
- Biological: Golimumab 50 mgBiological: PlaceboBiological: Golimumab 100 mgBiological: Golimumab 200 mg
- First Posted Date
- 2007-06-20
- Last Posted Date
- 2016-04-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1228
- Registration Number
- NCT00488631
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
Phase 2
Completed
- Conditions
- Colitis, Ulcerative
- Interventions
- Biological: Golimumab 100 mgBiological: Golimumab 200 mgBiological: PlaceboBiological: Golimumab 400 mgBiological: Golimumab 50 mg
- First Posted Date
- 2007-06-18
- Last Posted Date
- 2014-02-17
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1065
- Registration Number
- NCT00487539
Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer
Phase 1
Completed
- Conditions
- Prostate Neoplasms
- Interventions
- First Posted Date
- 2007-05-15
- Last Posted Date
- 2014-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 66
- Registration Number
- NCT00473746
© Copyright 2025. All Rights Reserved by MedPath